The risk of cardiovascular events has hampered sales of testosterone replacement therapies, and numerous studies providing evidence of adverse events associated with the synthetic hormones are causing many people to look at the products in a negative light. These are just some barriers manufacturers of testosterone treatments face in the near future, an analyst with Transparency Market Research (TMR) predicts.
Sales of testosterone replacement therapies have boomed in recent years with new formulations and brands entering the market, each pushing products through heavy direct-to-consumer marketing campaigns. The companies have even coined the phrase “Low T,” and suggested to men that a testosterone boost could cure ails such as low libido, weight gain, muscle loss and moodiness.
But testosterone treatments are intended for men with hypogonadism, a condition in which the body does not produce enough of the hormone testosterone. Levels naturally drop as men age, but the Food and Drug Administration (FDA) has made it clear that testosterone therapy is not intended for age-related hypogonadism.
Regardless, testosterone manufacturers see the aging population as a target for future sales. Riding the highest crest of that wave is AbbVie’s AndroGel, a TMR study found. Following close behind are products from Endo Pharmaceuticals, Eli Lilly and Company, Allergan plc, and Bayer AG.
Analysts say that even though the major testosterone manufacturers face patent expirations that could bite into revenues, as men become more familiar with testosterone therapy they are looking for more convenient formulations beyond injections or topical gels. Thus, the industry has stepped up and is developing formulations including nasal sprays and oral tablets.
Sales still remain strong despite studies that have linked testosterone treatments to an increased risk of blood clots, heart attacks, strokes and death. “This is perhaps the greatest challenge that companies in the TRT (testosterone replacement therapy) market will have to overcome,” one TMR analyst surmised.
Source: PR Newswire